Terms: = Ovarian cancer AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716
27 results:
1. Multifactor assessment of ovarian cancer reveals immunologically interpretable molecular subtypes with distinct prognoses.
Guo Y; Li S; Li C; Wang L; Ning W
Front Immunol; 2023; 14():1326018. PubMed ID: 38143770
[TBL] [Abstract] [Full Text] [Related]
2. Mechanisms of carboplatin- and paclitaxel-dependent induction of premature senescence and pro-cancerogenic conversion of normal peritoneal mesothelium and fibroblasts.
Rutecki S; Pakuła-Iwańska M; Leśniewska-Bocianowska A; Matuszewska J; Rychlewski D; Uruski P; Stryczyński Ł; Naumowicz E; Szubert S; Tykarski A; Mikuła-Pietrasik J; Książek K
J Pathol; 2024 Feb; 262(2):198-211. PubMed ID: 37941520
[TBL] [Abstract] [Full Text] [Related]
3. m6A-modified circNFIX promotes ovarian cancer progression and immune escape via activating IL-6R/jak1/STAT3 signaling by sponging miR-647.
Wang R; Ye H; Yang B; Ao M; Yu X; Wu Y; Xi M; Hou M
Int Immunopharmacol; 2023 Nov; 124(Pt A):110879. PubMed ID: 37713785
[TBL] [Abstract] [Full Text] [Related]
4. IFNγ induces Bcl3 expression by jak1/STAT1/p65 signaling, resulting in increased IL-8 expression in ovarian cancer cells.
Gaire B; Padmanabhan S; Zou Y; Uddin MM; Reddy SU; Vancurova I
FEBS Open Bio; 2023 Aug; 13(8):1495-1506. PubMed ID: 37151134
[TBL] [Abstract] [Full Text] [Related]
5. Extracellular vesicle-packaged miR-181c-5p from epithelial ovarian cancer cells promotes M2 polarization of tumor-associated macrophages via the KAT2B/HOXA10 axis.
Yang S; Zhao H; Xiao W; Shao L; Zhao C; Sun P
J Gene Med; 2022 Oct; 24(10):e3446. PubMed ID: 36027869
[TBL] [Abstract] [Full Text] [Related]
6. IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by jak1, STAT1 and IRF1 signaling.
Padmanabhan S; Gaire B; Zou Y; Uddin MM; Vancurova I
Cell Signal; 2022 Sep; 97():110400. PubMed ID: 35820543
[TBL] [Abstract] [Full Text] [Related]
7. Arachidonic acid, a clinically adverse mediator in the ovarian cancer microenvironment, impairs JAK-STAT signaling in macrophages by perturbing lipid raft structures.
Hammoud MK; Dietze R; Pesek J; Finkernagel F; Unger A; Bieringer T; Nist A; Stiewe T; Bhagwat AM; Nockher WA; Reinartz S; Müller-Brüsselbach S; Graumann J; Müller R
Mol Oncol; 2022 Sep; 16(17):3146-3166. PubMed ID: 35451191
[TBL] [Abstract] [Full Text] [Related]
8. Effects of Vitexin, a Natural Flavonoid Glycoside, on the Proliferation, Invasion, and Apoptosis of Human U251 Glioblastoma Cells.
Huang J; Zhou Y; Zhong X; Su F; Xu L
Oxid Med Cell Longev; 2022; 2022():3129155. PubMed ID: 35281458
[TBL] [Abstract] [Full Text] [Related]
9. IFNγ induces jak1/STAT1/p65 NFκB-dependent interleukin-8 expression in ovarian cancer cells, resulting in their increased migration.
Padmanabhan S; Gaire B; Zou Y; Uddin MM; DeLeon D; Vancurova I
Int J Biochem Cell Biol; 2021 Dec; 141():106093. PubMed ID: 34626802
[TBL] [Abstract] [Full Text] [Related]
10. CircMTO1: A circular RNA with roles in the carcinogenesis.
Ghafouri-Fard S; Khoshbakht T; Bahranian A; Taheri M; Hallajnejad M
Biomed Pharmacother; 2021 Oct; 142():112025. PubMed ID: 34392090
[TBL] [Abstract] [Full Text] [Related]
11. Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting.
Wu Z; Tao H; Zhang S; Wang X; Ma J; Li R; Liu Z; Wang J; Cui P; Chen S; Di H; Huang Z; Zheng X; Hu Y
Cancer Immunol Immunother; 2021 Oct; 70(10):2971-2980. PubMed ID: 33740125
[TBL] [Abstract] [Full Text] [Related]
12. Signal transducer and activator of transcription (STAT) 1 and STAT3 are expressed in the human ovary and have Janus kinase 1-independent functions in the COV434 human granulosa cell line.
Frost ER; Ford EA; Peters AE; Reed NL; McLaughlin EA; Baker MA; Lovell-Badge R; Sutherland JM
Reprod Fertil Dev; 2020 Aug; 32(12):1027-1039. PubMed ID: 32758351
[TBL] [Abstract] [Full Text] [Related]
13. Synthesis and biological evaluation of novel pyrazolo[1,5-a]pyrimidines: Discovery of a selective inhibitor of jak1 JH2 pseudokinase and VPS34.
Singleton JD; Dass R; Neubert NR; Smith RM; Webber Z; Hansen MDH; Peterson MA
Bioorg Med Chem Lett; 2020 Jan; 30(2):126813. PubMed ID: 31831383
[TBL] [Abstract] [Full Text] [Related]
14. Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer.
Liu S; Matsuzaki J; Wei L; Tsuji T; Battaglia S; Hu Q; Cortes E; Wong L; Yan L; Long M; Miliotto A; Bateman NW; Lele SB; Chodon T; Koya RC; Yao S; Zhu Q; Conrads TP; Wang J; Maxwell GL; Lugade AA; Odunsi K
J Immunother Cancer; 2019 Jun; 7(1):156. PubMed ID: 31221207
[TBL] [Abstract] [Full Text] [Related]
15. A comparison of two months pretreatment with GnRH agonists with or without an aromatase inhibitor in women with ultrasound-diagnosed ovarian endometriomas undergoing IVF.
Cantor A; Tannus S; Son WY; Tan SL; Dahan MH
Reprod Biomed Online; 2019 Apr; 38(4):520-527. PubMed ID: 30935663
[TBL] [Abstract] [Full Text] [Related]
16. Molecular Pathology and Novel Clinical Therapy for Uterine Leiomyosarcoma.
Hayashi T; Kawano M; Ichimura T; Ida K; Ando H; Zharhary D; Kanai Y; Aburatani H; Tonegawa S; Shiozawa T; Yaegashi N; Konishi I
Anticancer Res; 2016 Oct; 36(10):4997-5007. PubMed ID: 27798858
[TBL] [Abstract] [Full Text] [Related]
17. Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS.
Tavallai M; Booth L; Roberts JL; McGuire WP; Poklepovic A; Dent P
Oncotarget; 2016 Apr; 7(14):17290-300. PubMed ID: 26981780
[TBL] [Abstract] [Full Text] [Related]
18. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
[TBL] [Abstract] [Full Text] [Related]
19. Targeting jak1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.
Wen W; Liang W; Wu J; Kowolik CM; Buettner R; Scuto A; Hsieh MY; Hong H; Brown CE; Forman SJ; Horne D; Morgan R; Wakabayashi M; Dellinger TH; Han ES; Yim JH; Jove R
Mol Cancer Ther; 2014 Dec; 13(12):3037-48. PubMed ID: 25319391
[TBL] [Abstract] [Full Text] [Related]
20. Vitamin D receptor FokI, BsmI, ApaI, and TaqI polymorphisms and susceptibility to ovarian cancer: a meta-analysis.
Song GG; Lee YH
Immunol Invest; 2013; 42(7):661-72. PubMed ID: 24004063
[TBL] [Abstract] [Full Text] [Related]
[Next]
